[ 1] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 2] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 3] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 4] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 5] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 6] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 7] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 8] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 9] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 10] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 11] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 12] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 13] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 14] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 15] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 16] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 17] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 18] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 19] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 20] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 21] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 22] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 23] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 24] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 25] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 26] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 27] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 28] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 29] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 30] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 31] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 32] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 33] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 34] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 35] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 36] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 37] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 38] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 39] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 40] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 41] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 42] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 43] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 44] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 45] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 46] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 47] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 48] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 49] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 50] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 51] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 52] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 53] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 54] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 55] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 56] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 57] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 58] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [ 59] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [ 60] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 61] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 62] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 63] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 64] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 65] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 66] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 67] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 68] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 69] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [ 70] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [ 71] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 72] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 73] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 74] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 75] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 76] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 77] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 78] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 79] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 80] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [ 81] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [ 82] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 83] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 84] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 85] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [ 86] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 87] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 88] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [ 89] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 90] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 91] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [ 92] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [ 93] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [ 94] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [ 95] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [ 96] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 97] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [ 98] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [ 99] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [100] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [101] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [102] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [103] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [104] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [105] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [106] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [107] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [108] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [109] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [110] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [111] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [112] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [113] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [114] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [115] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [116] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [117] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [118] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [119] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [120] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [121] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [122] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [123] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [124] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [125] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [126] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [127] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [128] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [129] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [130] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [131] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [132] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [133] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [134] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [135] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [136] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [137] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [138] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [139] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [140] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [141] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [142] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [143] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [144] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [145] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [146] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [147] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [148] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [149] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [150] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [151] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [152] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [153] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [154] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [155] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [156] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [157] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [158] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [159] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [160] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [161] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [162] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [163] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [164] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [165] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [166] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [167] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [168] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [169] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [170] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [171] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [172] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [173] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [174] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [175] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [176] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [177] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [178] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [179] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [180] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [181] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [182] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [183] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [184] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [185] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [186] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [187] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [188] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [189] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [190] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [191] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [192] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [193] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [194] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [195] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [196] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [197] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [198] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [199] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [200] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [201] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [202] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [203] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [204] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [205] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [206] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [207] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [208] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [209] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [210] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [211] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [212] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [213] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [214] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [215] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [216] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [217] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [218] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [219] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [220] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [221] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [222] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [223] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [224] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [225] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [226] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [227] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [228] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [229] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [230] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [231] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [232] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [233] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [234] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [235] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [236] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [237] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [238] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [239] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [240] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [241] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [242] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [243] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [244] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [245] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [246] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [247] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [248] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [249] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [250] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [251] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [252] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [253] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [254] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [255] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [256] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [257] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [258] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [259] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [260] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [261] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [262] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [263] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [264] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [265] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [266] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [267] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [268] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [269] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [270] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [271] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [272] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [273] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [274] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [275] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [276] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [277] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [278] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [279] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [280] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [281] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [282] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [283] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [284] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [285] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [286] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [287] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [288] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [289] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [290] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [291] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [292] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [293] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [294] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [295] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [296] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [297] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [298] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [299] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [300] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [301] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [302] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [303] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [304] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [305] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [306] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [307] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [308] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [309] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [310] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [311] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [312] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [313] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [314] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [315] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [316] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [317] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [318] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [319] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [320] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [321] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [322] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [323] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [324] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [325] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [326] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [327] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [328] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [329] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [330] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [331] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [332] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [333] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [334] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [335] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [336] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [337] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [338] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [339] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [340] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [341] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [342] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [343] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [344] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [345] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [346] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [347] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [348] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [349] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [350] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [351] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [352] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [353] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [354] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [355] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [356] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [357] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [358] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [359] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [360] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [361] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [362] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [363] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [364] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [365] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [366] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [367] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [368] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [369] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [370] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [371] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [372] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [373] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [374] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [375] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [376] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [377] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [378] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [379] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [380] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [381] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [382] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [383] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [384] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [385] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [386] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [387] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [388] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [389] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [390] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [391] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [392] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [393] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [394] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [395] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [396] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [397] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [398] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [399] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [400] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [401] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [402] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [403] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [404] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [405] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [406] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [407] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [408] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [409] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [410] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [411] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [412] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [413] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [414] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [415] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [416] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [417] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [418] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [419] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [420] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [421] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [422] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [423] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [424] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [425] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [426] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [427] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [428] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [429] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [430] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [431] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [432] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [433] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [434] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [435] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [436] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [437] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [438] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [439] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [440] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [441] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [442] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [443] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [444] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [445] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [446] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [447] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [448] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [449] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [450] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [451] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [452] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [453] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [454] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [455] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [456] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [457] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [458] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [459] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [460] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [461] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [462] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [463] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [464] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [465] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [466] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [467] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [468] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [469] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [470] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [471] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [472] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [473] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [474] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [475] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [476] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [477] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [478] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [479] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [480] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [481] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [482] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [483] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [484] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [485] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [486] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [487] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [488] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [489] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [490] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [491] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [492] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [493] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [494] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [495] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [496] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [497] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [498] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [499] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [500] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [501] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [502] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [503] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [504] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [505] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [506] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [507] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [508] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [509] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [510] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [511] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [512] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [513] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [514] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [515] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [516] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [517] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [518] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [519] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [520] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [521] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [522] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [523] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [524] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [525] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [526] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [527] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [528] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [529] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [530] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [531] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [532] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [533] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [534] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [535] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [536] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [537] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [538] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [539] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [540] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [541] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [542] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [543] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [544] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [545] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [546] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [547] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [548] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [549] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [550] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [551] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [552] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [553] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [554] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [555] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [556] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [557] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [558] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [559] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [560] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [561] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [562] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [563] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [564] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [565] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [566] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [567] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [568] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [569] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [570] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [571] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [572] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [573] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [574] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [575] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [576] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [577] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [578] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [579] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [580] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [581] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [582] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [583] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [584] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [585] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [586] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [587] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [588] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [589] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [590] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [591] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [592] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [593] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [594] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [595] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [596] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [597] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [598] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [599] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [600] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [601] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [602] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [603] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [604] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [605] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [606] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [607] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [608] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [609] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [610] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [611] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [612] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [613] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [614] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [615] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [616] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [617] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [618] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [619] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [620] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [621] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [622] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [623] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [624] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [625] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [626] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [627] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [628] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [629] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [630] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [631] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [632] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [633] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [634] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [635] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [636] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [637] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [638] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [639] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [640] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [641] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [642] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [643] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [644] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [645] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [646] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [647] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [648] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [649] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [650] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [651] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [652] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [653] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [654] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [655] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [656] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [657] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [658] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [659] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [660] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [661] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [662] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [663] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [664] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [665] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [666] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [667] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [668] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [669] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [670] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [671] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [672] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [673] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [674] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [675] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [676] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [677] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [678] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [679] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [680] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [681] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [682] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [683] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [684] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [685] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [686] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [687] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [688] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [689] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [690] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [691] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [692] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [693] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [694] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [695] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [696] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [697] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [698] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [699] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [700] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [701] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [702] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [703] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [704] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [705] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [706] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [707] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [708] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [709] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [710] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [711] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [712] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [713] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [714] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [715] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [716] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [717] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [718] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [719] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [720] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [721] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [722] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [723] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [724] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [725] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [726] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [727] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [728] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [729] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [730] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [731] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [732] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [733] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [734] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [735] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [736] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [737] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [738] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [739] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [740] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [741] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [742] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [743] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [744] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [745] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [746] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [747] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [748] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [749] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [750] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [751] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [752] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [753] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [754] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [755] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [756] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [757] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [758] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [759] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [760] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [761] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [762] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [763] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [764] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [765] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [766] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [767] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [768] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [769] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [770] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [771] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [772] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [773] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [774] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [775] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [776] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [777] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [778] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [779] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [780] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [781] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [782] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [783] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [784] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [785] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [786] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [787] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [788] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [789] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [790] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [791] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [792] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [793] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [794] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [795] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [796] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [797] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [798] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [799] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [800] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [801] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [802] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [803] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [804] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [805] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [806] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [807] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [808] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [809] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [810] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [811] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [812] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [813] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [814] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [815] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [816] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [817] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [818] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [819] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [820] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [821] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [822] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [823] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [824] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [825] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [826] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [827] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [828] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [829] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [830] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [831] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [832] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [833] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [834] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [835] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [836] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [837] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [838] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [839] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [840] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [841] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [842] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [843] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [844] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [845] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [846] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [847] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [848] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [849] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [850] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [851] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [852] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [853] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [854] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [855] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [856] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [857] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [858] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [859] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [860] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [861] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [862] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [863] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [864] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [865] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [866] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [867] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [868] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [869] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [870] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [871] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [872] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [873] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [874] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [875] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [876] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [877] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [878] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [879] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [880] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [881] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [882] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [883] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [884] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [885] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [886] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [887] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [888] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [889] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [890] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [891] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [892] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [893] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [894] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [895] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [896] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [897] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [898] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [899] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [900] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [901] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [902] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [903] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [904] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [905] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [906] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [907] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [908] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [909] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [910] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [911] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [912] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [913] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [914] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [915] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [916] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [917] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [918] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [919] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [920] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [921] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [922] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [923] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [924] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [925] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [926] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [927] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [928] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [929] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [930] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [931] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [932] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [933] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [934] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [935] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [936] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [937] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [938] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [939] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [940] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [941] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [942] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [943] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [944] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [945] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [946] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [947] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [948] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [949] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [950] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [951] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [952] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [953] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [954] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [955] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [956] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [957] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [958] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [959] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [960] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [961] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [962] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [963] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [964] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [965] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [966] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [967] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [968] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [969] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [970] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [971] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [972] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [973] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [974] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [975] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [976] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [977] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [978] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [979] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [980] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [981] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [982] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [983] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [984] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [985] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [986] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [987] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [988] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [989] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [990] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [991] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [992] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [993] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [994] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [995] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [996] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [997] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [998] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [999] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1000] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1001] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1002] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1003] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [1004] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1005] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [1006] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1007] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1008] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1009] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1010] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1011] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1012] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [1013] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1014] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1015] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1016] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1017] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1018] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1019] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1020] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1021] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1022] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1023] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1024] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1025] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1026] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1027] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1028] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [1029] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1030] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1031] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1032] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1033] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1034] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1035] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [1036] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [1037] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [1038] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1039] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1040] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1041] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1042] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1043] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1044] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1045] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1046] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1047] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [1048] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1049] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [1050] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1051] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1052] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1053] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1054] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1055] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1056] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [1057] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1058] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1059] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1060] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1061] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1062] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1063] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1064] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1065] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1066] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1067] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1068] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1069] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1070] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1071] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1072] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [1073] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1074] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1075] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1076] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1077] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1078] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1079] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [1080] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [1081] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [1082] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1083] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1084] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1085] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1086] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1087] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1088] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1089] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1090] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1091] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [1092] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1093] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [1094] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1095] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1096] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1097] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1098] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1099] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1100] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [1101] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1102] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1103] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1104] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1105] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1106] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1107] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1108] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1109] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1110] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1111] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1112] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1113] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1114] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1115] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1116] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [1117] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1118] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1119] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1120] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1121] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1122] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1123] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [1124] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [1125] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [1126] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1127] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1128] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1129] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1130] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1131] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1132] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1133] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1134] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1135] Press Release (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Please find attached herewith Press Release of the Financial Results for the quarter ended 31st December 2025.". [1136] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1137] Press Release (2026-02-04)/Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2026, titled Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63% . [1138] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1139] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1140] Press Release (2026-04-01)/Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated April 01, 2026, titled Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India . [1141] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1142] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1143] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1144] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [1145] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1146] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1147] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1148] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1149] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1150] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1151] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1152] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1153] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1154] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1155] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1156] General Updates (2026-02-10)/Nephrocare Health Services Limited has informed the Exchange and attached herewith presentation being made to Investor/ Analyst on the financial results for the quarter and nine months ended 31st December, 2025. [1157] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1158] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1159] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1160] Press Release (2026-02-05)/Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025". [1161] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1162] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1163] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1164] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1165] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1166] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1167] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [1168] Outcome of Board Meeting (2026-01-28)/Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. [1169] Press Release (2026-01-30)/Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025". [1170] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1171] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1172] Press Release (2026-02-05)/Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year". [1173] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1174] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1175] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1176] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026 [1177] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-02)/Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026